Minapharm Pharmaceuticals S.A.E. specializes in developing, manufacturing and marketing prescription pharmaceutical products. The products are for the treatment of gastroenterological, ophthalmologic, cardiovascular, genetic, dermatological, orthopedic diseases, etc.

Employees

Sector

Pharmaceuticals

Calendar

08-12 Ex-dividend date - 1.25 EGP

More about the company

Quotes

Date	Price	Change	Volume
06/08/26	EGP 783.35	-1.34%	6,659
05/08/26	EGP 794.00	+0.02%	2,035
04/08/26	EGP 793.88	-3.01%	10,171
03/08/26	EGP 818.51	+4.78%	27,953
02/08/26	EGP 781.20	+5.55%	8,069

End-of-day quote Egyptian Exchange

More quotes

Income Statement and Estimates

More financial data

End-of-day quote Egyptian Exchange Other stock markets 06/08/2026			5-day change	1st Jan Change
783.35 ^EGP	-1.34%		+5.85%	+124.33%

06-10	MINAPHARM Pharmaceuticals Reports Earnings Results for the Full Year Ended December 31, 2025	CI
05-05	Minapharm pharmaceuticals FY standalone net profit EGP 57.5 million	RE

Market Cap	9.23B 185M 160M 150M 137M 258M 17.64B 262M 1.76B 689M 8.84B 696M 681M 29.23B	P/E 2024	14x	P/E 2025	584x
Enterprise Value	10.34B 208M 180M 168M 154M 289M 19.76B 294M 1.97B 772M 9.9B 780M 763M 32.74B	EV / Sales 2024	0.78x	EV / Sales 2025	0.81x
Free-Float	14.5%	Yield 2024	1.54%	Yield 2025	-

06-10	MINAPHARM Pharmaceuticals Reports Earnings Results for the Full Year Ended December 31, 2025	CI
05-05	Minapharm pharmaceuticals FY standalone net profit EGP 57.5 million	RE
11-30	Minapharm Pharmaceuticals Q3 consol profit egp 16.8 million	RE
11-30	MINAPHARM Pharmaceuticals Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
14/09/25	MINAPHARM Pharmaceuticals Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
14/09/25	Minapharm Pharmaceuticals Q2 consol profit EGP 40 million	RE
27/07/25	MINAPHARM Pharmaceuticals Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
27/07/25	Minapharm Pharmaceuticals Q1 consol net loss EGP 2 million	RE
12/06/25	MINAPHARM Pharmaceuticals Reports Earnings Results for the Full Year Ended December 31, 2024	CI
12/06/25	Minapharm Pharmaceuticals FY Colsol Net Profit EGP 161.1 Million	RE
26/05/25	Minapharm Pharmaceuticals FY Standalone Profit EGP 162.8 Million	RE
03/12/24	MINAPHARM Pharmaceuticals Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	CI
01/09/24	MINAPHARM Pharmaceuticals Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	CI

07/07/25	EBRD, Admaius Capital plan to acquire 15%-20% of Egyptian Minapharm Pharmaceuticals	AQ
26/03/25	African Development Bank Approves Eur 15 Million Loan to Boost Biosimilars' Development and Production in Egypt	AQ
05/10/23	SaudiVax, Minapharm, and MiGenTra Sign a Memorandum of Understanding towards a Strategic Partnership in Saudi Arabia and the Gulf Cooperation Countries	AQ
04/10/23	SaudiVax, Minapharm, and MiGenTra Sign a Memorandum of Understanding towards a Strategic Partnership in Saudi Arabia and the Gulf Cooperation Countries This landmark MOU marks a significant step towards ensuring national health security and achieving biomanufacturing autonomy in Saudi Arabia	AQ
06/03/23	Participants Dosed of Adessia® in Germany in a Phase 1 Trial, a First for an Adalimumab Biosimilar Candidate Developed in Africa	AQ

MINAPHARM Pharmaceuticals Stock

Stocks

MIPH

EGS380G1C011

Pharmaceuticals

Valuation: MINAPHARM Pharmaceuticals

Chart: MINAPHARM Pharmaceuticals

Latest news : MINAPHARM Pharmaceuticals

Press Releases: MINAPHARM Pharmaceuticals

Quotes and Performance

Course Extremes

Managers and Directors: MINAPHARM Pharmaceuticals

Generic Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

1 day	-1.34%
1 week	+5.85%
Current month	+5.85%
1 month	+14.77%
3 months	+13.12%
6 months	+129.61%
Current year	+124.33%

1 week	740.45	831
1 month	685.15	831
Current year	320.23	831
1 year	230	831
3 years	145	831
5 years	97	831
10 years	45	831

Manager	Title	Age	Since
Shaheer Wafeeq Sa'ad Al-Bardissy CEO	Chief Executive Officer	-	-
Wafik El-Bardissy CEO	Chief Executive Officer	-	19/10/2010
Rafiq Raymond DFI	Director of Finance/CFO	-	-

Director	Title	Age	Since
Wafik El-Bardissy CHM	Chairman	-	18/10/2010
Anwar Nasr Mekhaeel BRD	Director/Board Member	-	18/10/2010
Amr Mohamed Sobhi Hamza El-Shabrawishy BRD	Director/Board Member	-	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
MINAPHARM PHARMACEUTICALS	-1.34%	+5.85%	+229.39%	+263.79%	185M
SUN PHARMACEUTICAL INDUSTRIES LTD.	-0.31%	-2.29%	+21.68%	+67.56%	49.03B
OTSUKA HOLDINGS CO., LTD.	+4.40%	+14.46%	+66.32%	+142.60%	42.33B
CIPLA LIMITED	-0.89%	-0.64%	-1.82%	+19.63%	12.43B
ZYDUS LIFESCIENCES LIMITED	+0.56%	-1.12%	+17.97%	+70.05%	11.68B
KRKA, D. D.	+0.19%	+0.77%	+31.08%	+139.91%	9.12B
GEDEON RICHTER	+1.99%	+4.41%	+20.08%	+36.28%	7.15B
ONO PHARMACEUTICAL CO., LTD.	+1.82%	-0.15%	+39.86%	-12.61%	7.09B
GLENMARK PHARMACEUTICALS LIMITED	+0.40%	+2.02%	+10.49%	+179.30%	6.76B
SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD.	+6.44%	+8.26%	-24.87%	+30.54%	5.95B
Average	+1.33%	+2.49%	+41.02%	+93.71%	15.17B
Weighted average by Cap.	+1.56%	+3.75%	+31.19%	+87.65%

	2024	2025
Net sales	5.66B 114M 98.4M 91.9M 84.3M 159M 10.83B 161M 1.08B 423M 5.43B 427M 418M 17.94B	6.44B 129M 112M 104M 95.81M 180M 12.31B 183M 1.23B 481M 6.17B 486M 475M 20.39B
Net income	157M 3.15M 2.73M 2.55M 2.34M 4.4M 300M 4.47M 29.89M 11.73M 150M 11.84M 11.59M 497M	40.22M 808K 699K 652K 598K 1.13M 76.86M 1.14M 7.65M 3M 38.53M 3.03M 2.97M 127M
Net Debt	2.6B 52.18M 45.13M 42.15M 38.66M 72.72M 4.97B 73.88M 495M 194M 2.49B 196M 192M 8.23B	1.11B 22.29M 19.28M 18.01M 16.52M 31.07M 2.12B 31.57M 211M 82.93M 1.06B 83.72M 81.89M 3.52B